Abbott’s response to the Liverpool Reviews and Implementation Group Technology Assessment Report: adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review

Abbott welcomes the opportunity to comment on the assessment report developed by the Liverpool Reviews and Implementation Group for this appraisal. The executive summary outlines the key points regarding Abbott’s assessment of the clinical and cost-effectiveness of adalimumab for the treatment of AS. Information provided in italics has been quoted from the assessment report. Please note that these comments have considered only the evidence provided in the assessment report, as the Liverpool Reviews and Implementation Group (LRIG) economic model has not been released at the time of writing. Where possible Abbott has suggested alternative model configurations to be run following review of the evidence presented in the assessment report.